[{"id":"ef5ef83b-bc3d-4dc9-9b78-e271828de65e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06050122","created_at":"2023-09-22T14:10:44.436Z","updated_at":"2024-07-02T16:35:08.695Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","source_id_and_acronym":"NCT06050122","lead_sponsor":"Sol-Gel Technologies, Ltd.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/17/2024","start_date":" 03/17/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-19"},{"id":"d06e8af1-41a9-44ee-8b8e-7998ed004a25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03703310","created_at":"2021-01-18T18:08:53.199Z","updated_at":"2024-07-02T16:36:33.679Z","phase":"Phase 3","brief_title":"Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)","source_id_and_acronym":"NCT03703310","lead_sponsor":"PellePharm, Inc.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Completed","enrollment":" Enrollment 174","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 12/28/2020","primary_completion_date":" 12/28/2020","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2021-03-08"},{"id":"9d1cbdcb-bda6-4638-bfe0-b1a719e61280","acronym":"","url":"https://clinicaltrials.gov/study/NCT02762084","created_at":"2021-01-18T13:32:43.587Z","updated_at":"2024-07-02T16:36:42.846Z","phase":"Phase 2","brief_title":"Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients","source_id_and_acronym":"NCT02762084","lead_sponsor":"PellePharm, Inc.","biomarkers":" PTCH1 • GLI1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1 • GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 06/06/2016","start_date":" 06/06/2016","primary_txt":" Primary completion: 04/24/2017","primary_completion_date":" 04/24/2017","study_txt":" Completion: 04/24/2017","study_completion_date":" 04/24/2017","last_update_posted":"2020-07-23"},{"id":"eb9d7533-26cc-4fc3-b452-3eeed4ed6f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT02828111","created_at":"2021-01-18T13:51:59.563Z","updated_at":"2024-07-02T16:37:04.121Z","phase":"Phase 2","brief_title":"Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas","source_id_and_acronym":"NCT02828111","lead_sponsor":"PellePharm, Inc.","biomarkers":" GLI1","pipe":"","alterations":" ","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 11/11/2016","start_date":" 11/11/2016","primary_txt":" Primary completion: 11/09/2017","primary_completion_date":" 11/09/2017","study_txt":" Completion: 11/09/2017","study_completion_date":" 11/09/2017","last_update_posted":"2019-01-08"}]